Amicus Therapeutics Announces Posters And Presentations At Lysosomal Disease Network WORLD Symposium

CRANBURY, N.J., Feb. 7, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that 2 oral presentations and 5 posters related to its investigational pharmacological chaperones will be included at the 9 th Annual Lysosomal Disease Network WORLD Symposium ( LDN WORLD), to be held February 13-15, 2013 in Orlando, FL. The Company will host a conference call and live audio/visual webcast on Friday, February 15, 2013 at 11:30am ET to highlight the data presented at LDN WORLD.

Posters: Wednesday, February 13, 2013, 4:30-6:30pm ET and Thursday, February 14, 2013, 4:30-6:00pm ET

A Phase 2a Study to Investigate the Effect of a Single Dose of Migalastat HCl, a Pharmacological Chaperone, on Agalsidase Activity in Subjects with Fabry Disease – D. Warnock, D. Bichet, M. Holida, O. Goker-Alpan, K. Nicholls, M. Thomas, F. Eyskens, S. Shankar, G. Linthorst, M. Dasouki, F. K. Johnson, P. Boudes

A Phase 2a Study to Investigate Drug-Drug Interactions between Escalating Doses of AT2220 (Duvoglustat Hydrochloride) and Acid Alfa-Glucosidase in Subjects with Pompe Disease – P. Kishnani, M. Tarnopolsky, K. Sivakumar, M. Roberts, B. Byrne, O. Goker-Alpan, K. Guter, M. Pervaiz, M. Dasouki, T. Mozaffar, E. Finanger, F. Johnson, P. Boudes

Exploring the Use of a Co-Formulated Pharmacological Chaperone AT2220 with Recombinant Human Acid Alfa-Glucosidase for Pompe Disease – R. Khanna, S. Xu, Y. Lun, R. Soska, J. Feng, M. Frascella, A. Garcia, J. Flanagan, D. J. Lockhart, K. Valenzano

High Incidence of GLA Variants In A Non-Selected Heart Disease Patient Population Suggests That The Fabry Trait Is A Common Cardiovascular Genetic Risk Factor - R. Schiffman, S. Forni, C. Swift, X. Wu, D. J. Lockhart, M. Chee, T. Kitaoka, E. Chudin, S. Pond, N.H. McNeill, K. Sims, E.R. Benjamin, L. Sweetman

The Origins of Glucosylsphingosine in Gaucher Disease – J. Flanagan, B. Ranes, N. Brignol, R. Hamler, S.W. Clark

Oral Platform Presentations:

A Phase 2a Study to Investigate Drug-Drug Interactions between Escalating Doses of AT2220 (Duvoglustat Hydrochloride) and Acid Alfa-Glucosidase in Subjects with Pompe Disease – P. Kishnani, M. Tarnopolsky, K. Sivakumar, M. Roberts, B. Byrne, O. Goker-Alpan, K. Guter, M. Pervaiz, M. Dasouki, T. Mozaffar, E. Finanger, F. Johnson, P. Boudes
  • Friday, February 15, 2013, 9:15-9:30am ET (Mark Tarnopolsky, McMaster University)

Phase 3 Study of Migalastat HCl for Fabry Disease: Stage 1 Results. – K. Nicholls, D.P. Germain, C. Feliciani, S. Shankar, F. Ezgu, S.G. Janmohamed, S.M. Laing, R. Schroyer, A.C. Bragat, S. Sitaraman, P. Boudes
  • Friday, February 15, 2013, 10:30-10:45am ET (Fatih Ezgu, Gazi University)

Conference Call and Webcast:

John F. Crowley, Chairman and Chief Executive Officer, and members of the Amicus executive team will host a conference call and live audio/visual webcast on Friday, February 15, 2013 at 11:30am ET to discuss the data presented at LDN WORLD.

If you liked this article you might like

Remember, Fed News Is a Trigger for the Computers

Strong Action in Individual Stocks Starts to Feel a Bit Frothy

The Flippers Are at Work and the Bears Are Hopeful

Portola Shares Lower After Pricing Stock Offering - Biotech Movers

Time to Bring Amicus Therapeutics Into the 'FOLD'